The tweet was deleted by the author.
But we saved everything 🙂.
Edwards Lifesciences posted strong financial results, with revenue rising 10.5 percent and earnings increasing by 19 percent.
Sales of its mitral and tricuspid valve treatments jumped 44 percent, highlighting robust demand in the heart health business as the U.S. population continues to age.
View post on X Loading...
Shares of Edwards Lifesciences climbed 24 percent in the past month as strong heart valve earnings fueled gains, according to MarketWise reporting. The company’s recent results extend a growth streak driven by rising demand for heart valve treatments. MarketWise has also tracked significant investment activity elsewhere, with AI infrastructure spending surpassing $600 billion among leading tech firms.